Front Line Medical Technologies Inc. has achieved a significant milestone with the CE marking of its innovative COBRA-OS® (Control Of Bleeding, Resuscitation, Arterial Occlusion System) under the new European Medical Device Regulations. This ultra-low profile aortic occlusion device, the first of its kind approved through the new MDR system, is now available to medical providers in the EU, further expanding Front Line's market reach alongside its existing FDA clearance and Health Canada approval.
The COBRA-OS® stands out for its unique features, including its ultra-low profile design and simplified deployment process, enhancing efficiency in emergency and trauma care settings. Dr. Asha Parekh, CEO of Front Line Medical Technologies, emphasizes the company's commitment to patient-centric innovation, highlighting the COBRA-OS®'s role in advancing patient safety and improving outcomes. With this regulatory achievement, Front Line Medical Technologies solidifies its position as a key player in the industry and underscores its dedication to providing life-saving solutions to medical professionals worldwide.
